MODERNA, PFIZER REVEAL VACCINE TRIAL BLUEPRINTS

Two drug companies that are leading the race to develop coronavirus vaccines bowed to public pressure on Thursday, abandoning their traditional secrecy and releasing comprehensive road maps of how they are evaluating their vaccines.

The companies, Moderna and Pfizer, revealed details about how participants are being selected and monitored, the conditions under which the trials could be stopped early if there were problems, and the evidence researchers will use to determine whether people who got the vaccines were protected from Covid-19.

Moderna’s study will involve 30,000 participants, and Pfizer’s 44,000.

Companies typically share these documents after their studies are complete. The disclosures while the trials are still underway, a rare move, are aimed at addressing growing suspicion among Americans that President Trump’s drive to produce a vaccine before the election on November 3 could result in a product that was unsafe.

The plan released by Moderna included a likely timetable that could reach into next year for determining whether its vaccine works. It does not jibe with the president’s optimistic predictions of a vaccine widely available to the public in October.

Pfizer’s plan does not appear to estimate when its results could be available. Its chief executive has said repeatedly the company hopes to have an answer as early as October. Moderna has said it could have a result before the end of the year. Moderna’s 135-page plan, or protocol, indicated the company’s first analysis of early trial data might not be conducted until late December, though company officials now say they expect the initial analysis in November. In any case, there may not be enough information then to determine whether the vaccine works.

The disclosures are aimed at addressing growing suspicion among Americans that Trump’s drive to produce a vaccine before the election could result in an unsafe product